Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 May;18(3):438-445.
doi: 10.1016/j.jmoldx.2016.01.003. Epub 2016 Mar 3.

Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade

Yuan Ji  1 , Jennifer M Skierka  1 , Joseph H Blommel  1 , Brenda E Moore  1 , Douglas L VanCuyk  1 , Jamie K Bruflat  1 , Lisa M Peterson  1 , Tamra L Veldhuizen  2 , Numrah Fadra  3 , Sandra E Peterson  1 , Susan A Lagerstedt  1 , Laura J Train  1 , Linnea M Baudhuin  1 , Eric W Klee  4 , Matthew J Ferber  5 , Suzette J Bielinski  3 , Pedro J Caraballo  6 , Richard M Weinshilboum  7 , John L Black 3rd  8
Affiliations

Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade

Yuan Ji et al. J Mol Diagn. 2016 May.

Abstract

Significant barriers, such as lack of professional guidelines, specialized training for interpretation of pharmacogenomics (PGx) data, and insufficient evidence to support clinical utility, prevent preemptive PGx testing from being widely clinically implemented. The current study, as a pilot project for the Right Drug, Right Dose, Right Time-Using Genomic Data to Individualize Treatment Protocol, was designed to evaluate the impact of preemptive PGx and to optimize the workflow in the clinic setting. We used an 84-gene next-generation sequencing panel that included SLCO1B1, CYP2C19, CYP2C9, and VKORC1 together with a custom-designed CYP2D6 testing cascade to genotype the 1013 subjects in laboratories approved by the Clinical Laboratory Improvement Act. Actionable PGx variants were placed in patient's electronic medical records where integrated clinical decision support rules alert providers when a relevant medication is ordered. The fraction of this cohort carrying actionable PGx variant(s) in individual genes ranged from 30% (SLCO1B1) to 79% (CYP2D6). When considering all five genes together, 99% of the subjects carried an actionable PGx variant(s) in at least one gene. Our study provides evidence in favor of preemptive PGx testing by identifying the risk of a variant being present in the population we studied.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The RIGHT Protocol study design with a focus on five PGx genes. CDS, clinical decision support; EMR, electronic medical record; NGS, next-generation sequencing; PGx, pharmacogenomics; QC, quality control; RIGHT, Right Drug, Right Dose, Right Time–Using Genomic Data to Individualize Treatment.
Figure 2
Figure 2
Distributions of RIGHT subjects in CYP2D6, CYP2C9, CYP2C19, SLCO1B1*5, and VKORC1 categories. Percentage of subjects among the total RIGHT cohort for each of the predicted CYP2D6 (A), CYP2C9 (B), and CYP2C19 (C) metabolizer groups; percentage of subjects among the total RIGHT cohort carrying various genotypes for SLCO1B1*5 (TT, TC, or TT) and VKORC1 SNP rs9923231 (GG, GA, and AA) (D). EM, extensive metabolizer; IM, intermediate metabolizer; PM, poor metabolizer; RIGHT, Right Drug, Right Dose, Right Time–Using Genomic Data to Individualize Treatment; UM, ultrarapid metabolizer.
Figure 3
Figure 3
Percentage of RIGHT subjects among groups carrying actionable PGx variants in zero to five of the PGx genes. PGx, pharmacogenomics; RIGHT, Right Drug, Right Dose, Right Time–Using Genomic Data to Individualize Treatment.
Figure 4
Figure 4
Examples of CYP2C19 CDS alerts triggered for the RIGHT subjects at the point of care. A: Patient predicted to carry one single actionable PGx variant-triggered alert for one medication, clopidogrel. B: Patient predicted to carry one single actionable PGx variant-triggered alerts for two medications, codeine and tramadol. C: Patient predicted to carry actionable PGx variants in two genes that triggered alerts for several relevant drugs. CDS, clinical decision support; MICS, Mayo Integrated Clinical Systems; PGx, pharmacogenomics; RIGHT, Right Drug, Right Dose, Right Time–Using Genomic Data to Individualize Treatment.
See this image and copyright information in PMC

References

    1. Wang L., McLeod H.L., Weinshilboum R.M. Genomics and drug response. N Engl J Med. 2011;364:1144–1153. - PMC - PubMed
    1. U.S. Food and Drug Administration. Table of pharmacogenomic biomarkers in drug labeling. US Department of Health and Human Services, 2015. Available at http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/... (accessed December 24, 2015)
    1. Farrugia G., Weinshilboum R.M. Challenges in implementing genomic medicine: the Mayo Clinic Center for Individualized Medicine. Clin Pharmacol Ther. 2013;94:204–206. - PMC - PubMed
    1. Shuldiner A.R., Relling M.V., Peterson J.F., Hicks J.K., Freimuth R.R., Sadee W. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther. 2013;94:207–210. - PMC - PubMed
    1. Bielinski S.J., Olson J.E., Pathak J., Weinshilboum R.M., Wang L., Lyke K.J., Ryu E., Targonski P.V., Van Norstrand M.D., Hathcock M.A., Takahashi P.Y., McCormick J.B., Johnson K.J., Maschke K.J., Rohrer Vitek C.R., Ellingson M.S., Wieben E.D., Farrugia G., Morrisette J.A., Kruckeberg K.J., Bruflat J.K., Peterson L.M., Blommel J.H., Skierka J.M., Ferber M.J., Black J.L., Baudhuin L.M., Klee E.W., Ross J.L., Veldhuizen T.L., Schultz C.G., Caraballo P.J., Freimuth R.R., Chute C.G., Kullo I.J. Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol. Mayo Clin Proc. 2014;89:25–33. - PMC - PubMed

Publication types

Substances

LinkOut - more resources